Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Up 6.3% – What’s Next?

by · The Markets Daily

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report)’s share price traded up 6.3% during trading on Monday. The stock traded as high as $12.40 and last traded at $12.40. Approximately 400 shares traded hands during trading, a decline of 90% from the average session volume of 4,129 shares. The stock had previously closed at $11.67.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.00.

Read Our Latest Research Report on TLPPF

Telix Pharmaceuticals Stock Up 6.3%

The business’s fifty day moving average is $11.16 and its 200 day moving average is $10.34.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer imaging and treatment. Its platform combines radioactive isotopes with targeting molecules designed to identify or bind to specific biological markers associated with disease.

The company’s principal commercial product is Illuccix, a gallium-68 PSMA-PET imaging agent used to help detect and manage prostate cancer. Telix is also developing a pipeline of diagnostic and therapeutic radiopharmaceuticals targeting cancers including kidney, brain, and prostate tumors, as well as other medical conditions.

Founded in 2015 and headquartered in Melbourne, Australia, Telix serves healthcare markets across Australia, the United States, Europe, and other international regions through regulatory approvals, commercial partnerships, and distribution arrangements.

See Also